<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00154440</url>
  </required_header>
  <id_info>
    <org_study_id>HELYX Study</org_study_id>
    <nct_id>NCT00154440</nct_id>
  </id_info>
  <brief_title>Helicobacter – Lymphoma – Radiation Part I: Eradication, Part II: Radiation</brief_title>
  <official_title>Treatment of Low-Grade Gastric Non-Hodgkin‘s Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Type Stages IE &amp; II1E (HELYX-Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The first objective of this study is to confirm the results of complete remission of
      low-grade gastric MALT lymphoma stage IE &amp; II1E after H. pylori eradication on a larger
      number of patients (HELYX Part I). If there is no response to the antibiotic therapy, the
      role of radiotherapy on the course of gastric MALT lymphoma will be investigated as a
      consecutive therapeutic option for patients that are H. pylori- negative, t(11;18)-positive
      or failure candidates after eradication therapy. Furthermore, the method of radiation, and
      the radiation dose will be investigated and standardized. HELYX PART II is therefore a
      randomized equivalent study comparing the standard dose of 36Gy vs. a reduced dose of 25.2Gy
      locoregional. Additional molecular genetic analysis will be performed to try to understand
      pathogenetic mechanisms of lymphomagenesis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Experimental data have extended the knowledge of the mere association of gastric MALT
      lymphoma and infection with Helicobacter pylori. If we summarise the reports to date on the
      results of treatment of gastric low-grade MALT lymphoma in an early clinical stage (EI) by H.
      pylori eradication we find a complete remission figure of 77% in more than 200 patients.

      As a therapy with less side effects than radiation, surgery or chemotherapy and as a
      stomach-conserving treatment, eradication of H. pylori in patients with low-grade gastric
      MALT lymphoma in stages IE &amp; II1E should be the treatment of the choice within clinical
      trials since there are no long-term results available thus far. Besides, pretreatment patient
      selection and careful follow-up with endoscopy, biopsies and clinical staging including
      endoscopic ultrasonography is necessary. However, a five to ten year-follow-up will be
      necessary before the definitive value of Helicobacter pylori eradication can be established.
      Furthermore, since not all patients respond to this therapy research into the pathogenetic
      mechanisms of lymphomagenesis is inevitable.

      Approximately 20% of patients with antigen-positive, primary gastric low-grade MALT lymphoma
      in stage I will not respond to eradication therapy. Hence, a consecutive salvage therapy
      other than surgery is much needed. The aim of the second part of this study is to establish
      radiation therapy as a salvage therapy. Furthermore, the effect of a reduced radiation dose
      (25.2Gy) compared to the standard dose (36Gy) will be investigated with the aim of
      non-inferiority of both doses.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2001</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>remission status after eradication therapy 3-monthly</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>continuous complete remission (CCR) during follow-up</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>remission status after radiation therapy (36 Gy vs 25.2 Gy)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>continuous complete remission after radiation therapy during follow-up</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>endoscopic controls every 3 months during the first year</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endoscopic controls twice yearly in the second year after CR</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete tumor staging once yearly</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse after therapy after each intervention</measure>
  </secondary_outcome>
  <enrollment>200</enrollment>
  <condition>Lymphoma</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>proton pump inhibitor</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clarithromycin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amoxicillin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metronidazole</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically diagnosed, primary gastric low-grade B-cell MALT lymphoma stages IE or
             II1E, Helicobacter pylori-positive (in histology, urease test , and serology) for
             inclusion into HELYX part I

          -  histologically diagnosed, primary gastric low-grade B-cell MALT lymphoma stages IE or
             II1E, Helicobacter pylori-negative (in histology, urease test, and serology) for
             inclusion into HELYX part II

          -  patients who achieved a study end point of HELYX I: partial remission or no change 12
             months after successful antibiotic therapy for inclusion into HELYX part II,

          -  age &gt; 18 and &lt; 75 years

          -  Karnofsky-Index &gt; 60%

          -  sufficient liver function, defined as bilirubin &lt; 34µmol/l

          -  sufficient renal function, defined as creatinine &lt; 133µmol/l

          -  written informed consent

          -  complete clinical tumor staging

        Exclusion Criteria:

          -  primary gastric low-grade MALT lymphoma, stages &gt;II1E or gastric high-grade lymphoma
             or other lymphoma entities of the stomach e.g. lymphoblastic lymphoma or Burkitt’s
             lymphoma

          -  age &lt; 18 and &gt; 75 years

          -  Karnofsky-Index &lt; 60%

          -  insufficient liver and renal function (see above)

          -  HIV-infection

          -  pregnancy or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Morgner-Miehlke, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Med. Dept. I, University Hospital, Technical University Dresden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Morgner-Miehlke, MD, PhD</last_name>
    <phone>+49351458</phone>
    <phone_ext>2986</phone_ext>
    <email>andrea.morgner-miehlke@uniklinikum-dresden.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Renate Schmelz, MD</last_name>
    <phone>+49351458</phone>
    <phone_ext>4702/2986</phone_ext>
    <email>renate.schmelz@uniklinikum-dresden.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute for Pathology</name>
      <address>
        <city>Bayreuth</city>
        <state>Bavaria</state>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manfred Stolte, MD, PhD</last_name>
      <phone>+49921400</phone>
      <phone_ext>5600</phone_ext>
      <email>pathologie.klinikum@bnbt.de</email>
    </contact>
    <contact_backup>
      <last_name>Michael Vieth, MD, PhD</last_name>
      <phone>+49921400</phone>
      <phone_ext>5602</phone_ext>
      <email>Vieth.LKPathol@uni-bayreuth.de</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Vieth, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Med. Dept. I, Gastroenterology</name>
      <address>
        <city>Dresden</city>
        <state>Saxonia</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Ehninger, MD, PhD</last_name>
      <phone>+49251458</phone>
      <phone_ext>4190</phone_ext>
      <email>gerhard.ehninger@uniklinikum-dresden.de</email>
    </contact>
    <contact_backup>
      <last_name>Stephan Miehlke, MD, PhD</last_name>
      <phone>+49351458</phone>
      <phone_ext>5645</phone_ext>
      <email>stephan.miehlke@uniklinikum-dresden.de</email>
    </contact_backup>
    <investigator>
      <last_name>Stephan Miehlke, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. for Radiation Therapy &amp; Radiooncology, University Hospital</name>
      <address>
        <city>Germany</city>
        <state>Saxonia</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Herrmann, MD, PhD</last_name>
      <phone>+49351458</phone>
      <phone_ext>3373</phone_ext>
      <email>thomas.herrmann@uniklinikum-dresden.de</email>
    </contact>
    <contact_backup>
      <last_name>Monique Dawel, MD</last_name>
      <phone>+49351458</phone>
      <phone_ext>3373</phone_ext>
      <email>monique.dawel@uniklinikum-dresden.de</email>
    </contact_backup>
    <investigator>
      <last_name>Monique Dawel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Akagi T, Motegi M, Tamura A, Suzuki R, Hosokawa Y, Suzuki H, Ota H, Nakamura S, Morishima Y, Taniwaki M, Seto M. A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene. 1999 Oct 14;18(42):5785-94.</citation>
    <PMID>10523859</PMID>
  </reference>
  <reference>
    <citation>Alpen B, Neubauer A, Dierlamm J, Marynen P, Thiede C, Bayerdörfer E, Stolte M. Translocation t(11;18) absent in early gastric marginal zone B-cell lymphoma of MALT type responding to eradication of Helicobacter pylori infection. Blood. 2000 Jun 15;95(12):4014-5.</citation>
    <PMID>10939796</PMID>
  </reference>
  <reference>
    <citation>Bayerdörffer E, Neubauer A, Rudolph B, Thiede C, Lehn N, Eidt S, Stolte M. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet. 1995 Jun 24;345(8965):1591-4.</citation>
    <PMID>7783535</PMID>
  </reference>
  <reference>
    <citation>Hussell T, Isaacson PG, Crabtree JE, Spencer J. The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet. 1993 Sep 4;342(8871):571-4.</citation>
    <PMID>8102718</PMID>
  </reference>
  <reference>
    <citation>Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, Ye H, Molina T, Bouhnik Y, Hamoudi RA, Diss TC, Dogan A, Megraud F, Rambaud JC, Du MQ, Isaacson PG. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet. 2001 Jan 6;357(9249):39-40.</citation>
    <PMID>11197361</PMID>
  </reference>
  <reference>
    <citation>Neubauer A, Thiede C, Morgner A, Alpen B, Ritter M, Neubauer B, Wündisch T, Ehninger G, Stolte M, Bayerdörffer E. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst. 1997 Sep 17;89(18):1350-5.</citation>
    <PMID>9308704</PMID>
  </reference>
  <reference>
    <citation>Schechter NR, Portlock CS, Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol. 1998 May;16(5):1916-21.</citation>
    <PMID>9586910</PMID>
  </reference>
  <reference>
    <citation>Thiede C, Morgner A, Alpen B, Wündisch T, Herrmann J, Ritter M, Ehninger G, Stolte M, Bayerdörffer E, Neubauer A. What role does Helicobacter pylori eradication play in gastric MALT and gastric MALT lymphoma? Gastroenterology. 1997 Dec;113(6 Suppl):S61-4. Review.</citation>
    <PMID>9394762</PMID>
  </reference>
  <reference>
    <citation>Ruskoné-Fourmestraux A, Dragosics B, Morgner A, Wotherspoon A, De Jong D. Paris staging system for primary gastrointestinal lymphomas. Gut. 2003 Jun;52(6):912-3.</citation>
    <PMID>12740354</PMID>
  </reference>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>March 23, 2007</last_update_submitted>
  <last_update_submitted_qc>March 23, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2007</last_update_posted>
  <keyword>primary gastric MALT lymphoma</keyword>
  <keyword>Helicobacter pylori</keyword>
  <keyword>eradication therapy</keyword>
  <keyword>radiation</keyword>
  <keyword>marginal zone B-cell lymphoma</keyword>
  <keyword>Mucosa-associated Lymphoid Tissue</keyword>
  <keyword>B-cell Non-Hodgkin's Lymphoma of the stomach</keyword>
  <keyword>primary gastric lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

